nodes	percent_of_prediction	percent_of_DWPC	metapath
Cabergoline—Anorexia—Fluorouracil—pancreatic cancer	0.000693	0.00132	CcSEcCtD
Cabergoline—Hypotension—Gemcitabine—pancreatic cancer	0.000691	0.00132	CcSEcCtD
Cabergoline—Insomnia—Irinotecan—pancreatic cancer	0.000687	0.00131	CcSEcCtD
Cabergoline—Cardiac disorder—Docetaxel—pancreatic cancer	0.000686	0.00131	CcSEcCtD
Cabergoline—Vomiting—Tamoxifen—pancreatic cancer	0.000684	0.00131	CcSEcCtD
Cabergoline—Cardiac failure—Doxorubicin—pancreatic cancer	0.000683	0.0013	CcSEcCtD
Cabergoline—Paraesthesia—Irinotecan—pancreatic cancer	0.000682	0.0013	CcSEcCtD
Cabergoline—Hypotension—Fluorouracil—pancreatic cancer	0.00068	0.0013	CcSEcCtD
Cabergoline—Hypersensitivity—Sunitinib—pancreatic cancer	0.000679	0.0013	CcSEcCtD
Cabergoline—Rash—Tamoxifen—pancreatic cancer	0.000679	0.0013	CcSEcCtD
Cabergoline—Dermatitis—Tamoxifen—pancreatic cancer	0.000678	0.00129	CcSEcCtD
Cabergoline—Vomiting—Erlotinib—pancreatic cancer	0.000677	0.00129	CcSEcCtD
Cabergoline—Dyspnoea—Irinotecan—pancreatic cancer	0.000677	0.00129	CcSEcCtD
Cabergoline—Somnolence—Irinotecan—pancreatic cancer	0.000675	0.00129	CcSEcCtD
Cabergoline—Blood creatinine increased—Epirubicin—pancreatic cancer	0.000675	0.00129	CcSEcCtD
Cabergoline—Headache—Tamoxifen—pancreatic cancer	0.000674	0.00129	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000674	0.00129	CcSEcCtD
Cabergoline—Rash—Erlotinib—pancreatic cancer	0.000671	0.00128	CcSEcCtD
Cabergoline—Dermatitis—Erlotinib—pancreatic cancer	0.000671	0.00128	CcSEcCtD
Cabergoline—Insomnia—Gemcitabine—pancreatic cancer	0.000669	0.00128	CcSEcCtD
Cabergoline—Dyspepsia—Irinotecan—pancreatic cancer	0.000668	0.00128	CcSEcCtD
Cabergoline—Headache—Erlotinib—pancreatic cancer	0.000667	0.00127	CcSEcCtD
Cabergoline—Osteoarthritis—Doxorubicin—pancreatic cancer	0.000667	0.00127	CcSEcCtD
Cabergoline—Liver function test abnormal—Epirubicin—pancreatic cancer	0.000665	0.00127	CcSEcCtD
Cabergoline—Paraesthesia—Gemcitabine—pancreatic cancer	0.000664	0.00127	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000663	0.00126	CcSEcCtD
Cabergoline—Asthenia—Sunitinib—pancreatic cancer	0.000661	0.00126	CcSEcCtD
Cabergoline—Decreased appetite—Irinotecan—pancreatic cancer	0.00066	0.00126	CcSEcCtD
Cabergoline—Arrhythmia—Docetaxel—pancreatic cancer	0.00066	0.00126	CcSEcCtD
Cabergoline—Dyspnoea—Gemcitabine—pancreatic cancer	0.000659	0.00126	CcSEcCtD
Cabergoline—Abdominal pain upper—Epirubicin—pancreatic cancer	0.000658	0.00126	CcSEcCtD
Cabergoline—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000658	0.00126	CcSEcCtD
Cabergoline—Insomnia—Fluorouracil—pancreatic cancer	0.000658	0.00126	CcSEcCtD
Cabergoline—Somnolence—Gemcitabine—pancreatic cancer	0.000658	0.00126	CcSEcCtD
Cabergoline—Fatigue—Irinotecan—pancreatic cancer	0.000655	0.00125	CcSEcCtD
Cabergoline—Paraesthesia—Fluorouracil—pancreatic cancer	0.000653	0.00125	CcSEcCtD
Cabergoline—Alopecia—Docetaxel—pancreatic cancer	0.000653	0.00125	CcSEcCtD
Cabergoline—Pruritus—Sunitinib—pancreatic cancer	0.000652	0.00125	CcSEcCtD
Cabergoline—Constipation—Irinotecan—pancreatic cancer	0.000649	0.00124	CcSEcCtD
Cabergoline—Pain—Irinotecan—pancreatic cancer	0.000649	0.00124	CcSEcCtD
Cabergoline—Dyspnoea—Fluorouracil—pancreatic cancer	0.000648	0.00124	CcSEcCtD
Cabergoline—Somnolence—Fluorouracil—pancreatic cancer	0.000647	0.00123	CcSEcCtD
Cabergoline—Face oedema—Doxorubicin—pancreatic cancer	0.000643	0.00123	CcSEcCtD
Cabergoline—Decreased appetite—Gemcitabine—pancreatic cancer	0.000643	0.00123	CcSEcCtD
Cabergoline—Dyspepsia—Fluorouracil—pancreatic cancer	0.00064	0.00122	CcSEcCtD
Cabergoline—Nausea—Tamoxifen—pancreatic cancer	0.000639	0.00122	CcSEcCtD
Cabergoline—Fatigue—Gemcitabine—pancreatic cancer	0.000638	0.00122	CcSEcCtD
Cabergoline—Gastritis—Epirubicin—pancreatic cancer	0.000638	0.00122	CcSEcCtD
Cabergoline—Constipation—Gemcitabine—pancreatic cancer	0.000633	0.00121	CcSEcCtD
Cabergoline—Pain—Gemcitabine—pancreatic cancer	0.000633	0.00121	CcSEcCtD
Cabergoline—Nausea—Erlotinib—pancreatic cancer	0.000633	0.00121	CcSEcCtD
Cabergoline—Decreased appetite—Fluorouracil—pancreatic cancer	0.000632	0.00121	CcSEcCtD
Cabergoline—Diarrhoea—Sunitinib—pancreatic cancer	0.000631	0.0012	CcSEcCtD
Cabergoline—Feeling abnormal—Irinotecan—pancreatic cancer	0.000626	0.00119	CcSEcCtD
Cabergoline—Blood creatinine increased—Doxorubicin—pancreatic cancer	0.000624	0.00119	CcSEcCtD
Cabergoline—Influenza—Epirubicin—pancreatic cancer	0.000623	0.00119	CcSEcCtD
Cabergoline—Back pain—Docetaxel—pancreatic cancer	0.000622	0.00119	CcSEcCtD
Cabergoline—Pain—Fluorouracil—pancreatic cancer	0.000622	0.00119	CcSEcCtD
Cabergoline—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000621	0.00119	CcSEcCtD
Cabergoline—Muscle spasms—Docetaxel—pancreatic cancer	0.000618	0.00118	CcSEcCtD
Cabergoline—Liver function test abnormal—Doxorubicin—pancreatic cancer	0.000615	0.00117	CcSEcCtD
Cabergoline—Dizziness—Sunitinib—pancreatic cancer	0.00061	0.00116	CcSEcCtD
Cabergoline—Feeling abnormal—Gemcitabine—pancreatic cancer	0.00061	0.00116	CcSEcCtD
Cabergoline—Abdominal pain upper—Doxorubicin—pancreatic cancer	0.000609	0.00116	CcSEcCtD
Cabergoline—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000609	0.00116	CcSEcCtD
Cabergoline—Abdominal pain—Irinotecan—pancreatic cancer	0.0006	0.00115	CcSEcCtD
Cabergoline—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000599	0.00114	CcSEcCtD
Cabergoline—Bronchitis—Epirubicin—pancreatic cancer	0.000599	0.00114	CcSEcCtD
Cabergoline—Gastritis—Doxorubicin—pancreatic cancer	0.00059	0.00113	CcSEcCtD
Cabergoline—Vomiting—Sunitinib—pancreatic cancer	0.000586	0.00112	CcSEcCtD
Cabergoline—Rash—Sunitinib—pancreatic cancer	0.000581	0.00111	CcSEcCtD
Cabergoline—Dermatitis—Sunitinib—pancreatic cancer	0.000581	0.00111	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Epirubicin—pancreatic cancer	0.000579	0.0011	CcSEcCtD
Cabergoline—Headache—Sunitinib—pancreatic cancer	0.000577	0.0011	CcSEcCtD
Cabergoline—Syncope—Docetaxel—pancreatic cancer	0.000577	0.0011	CcSEcCtD
Cabergoline—Influenza—Doxorubicin—pancreatic cancer	0.000576	0.0011	CcSEcCtD
Cabergoline—Palpitations—Docetaxel—pancreatic cancer	0.000568	0.00109	CcSEcCtD
Cabergoline—Weight increased—Epirubicin—pancreatic cancer	0.000567	0.00108	CcSEcCtD
Cabergoline—Loss of consciousness—Docetaxel—pancreatic cancer	0.000565	0.00108	CcSEcCtD
Cabergoline—Weight decreased—Epirubicin—pancreatic cancer	0.000563	0.00108	CcSEcCtD
Cabergoline—Hypersensitivity—Irinotecan—pancreatic cancer	0.000559	0.00107	CcSEcCtD
Cabergoline—Pneumonia—Epirubicin—pancreatic cancer	0.000558	0.00107	CcSEcCtD
Cabergoline—Hypertension—Docetaxel—pancreatic cancer	0.000555	0.00106	CcSEcCtD
Cabergoline—Bronchitis—Doxorubicin—pancreatic cancer	0.000554	0.00106	CcSEcCtD
Cabergoline—Arthralgia—Docetaxel—pancreatic cancer	0.000548	0.00105	CcSEcCtD
Cabergoline—Nausea—Sunitinib—pancreatic cancer	0.000548	0.00105	CcSEcCtD
Cabergoline—Asthenia—Irinotecan—pancreatic cancer	0.000545	0.00104	CcSEcCtD
Cabergoline—Urinary tract infection—Epirubicin—pancreatic cancer	0.00054	0.00103	CcSEcCtD
Cabergoline—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000536	0.00102	CcSEcCtD
Cabergoline—Dry mouth—Docetaxel—pancreatic cancer	0.000536	0.00102	CcSEcCtD
Cabergoline—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	0.000535	0.00102	CcSEcCtD
Cabergoline—Asthenia—Gemcitabine—pancreatic cancer	0.000531	0.00101	CcSEcCtD
Cabergoline—Confusional state—Docetaxel—pancreatic cancer	0.000529	0.00101	CcSEcCtD
Cabergoline—Oedema—Docetaxel—pancreatic cancer	0.000525	0.001	CcSEcCtD
Cabergoline—Weight increased—Doxorubicin—pancreatic cancer	0.000524	0.001	CcSEcCtD
Cabergoline—Epistaxis—Epirubicin—pancreatic cancer	0.000524	0.001	CcSEcCtD
Cabergoline—Pruritus—Gemcitabine—pancreatic cancer	0.000523	0.000999	CcSEcCtD
Cabergoline—Weight decreased—Doxorubicin—pancreatic cancer	0.000521	0.000995	CcSEcCtD
Cabergoline—Diarrhoea—Irinotecan—pancreatic cancer	0.00052	0.000992	CcSEcCtD
Cabergoline—Pneumonia—Doxorubicin—pancreatic cancer	0.000517	0.000986	CcSEcCtD
Cabergoline—Shock—Docetaxel—pancreatic cancer	0.000516	0.000986	CcSEcCtD
Cabergoline—Pruritus—Fluorouracil—pancreatic cancer	0.000515	0.000982	CcSEcCtD
Cabergoline—Diarrhoea—Gemcitabine—pancreatic cancer	0.000506	0.000966	CcSEcCtD
Cabergoline—Dizziness—Irinotecan—pancreatic cancer	0.000502	0.000959	CcSEcCtD
Cabergoline—Anorexia—Docetaxel—pancreatic cancer	0.0005	0.000955	CcSEcCtD
Cabergoline—Rhinitis—Epirubicin—pancreatic cancer	0.0005	0.000954	CcSEcCtD
Cabergoline—Urinary tract infection—Doxorubicin—pancreatic cancer	0.000499	0.000953	CcSEcCtD
Cabergoline—Diarrhoea—Fluorouracil—pancreatic cancer	0.000498	0.00095	CcSEcCtD
Cabergoline—Oedema peripheral—Epirubicin—pancreatic cancer	0.000491	0.000937	CcSEcCtD
Cabergoline—Hypotension—Docetaxel—pancreatic cancer	0.00049	0.000936	CcSEcCtD
Cabergoline—Epistaxis—Doxorubicin—pancreatic cancer	0.000484	0.000925	CcSEcCtD
Cabergoline—Vomiting—Irinotecan—pancreatic cancer	0.000483	0.000922	CcSEcCtD
Cabergoline—Dizziness—Fluorouracil—pancreatic cancer	0.000481	0.000918	CcSEcCtD
Cabergoline—Visual impairment—Epirubicin—pancreatic cancer	0.00048	0.000917	CcSEcCtD
Cabergoline—Rash—Irinotecan—pancreatic cancer	0.000479	0.000914	CcSEcCtD
Cabergoline—Dermatitis—Irinotecan—pancreatic cancer	0.000478	0.000913	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000478	0.000913	CcSEcCtD
Cabergoline—Headache—Irinotecan—pancreatic cancer	0.000476	0.000908	CcSEcCtD
Cabergoline—Insomnia—Docetaxel—pancreatic cancer	0.000475	0.000906	CcSEcCtD
Cabergoline—Paraesthesia—Docetaxel—pancreatic cancer	0.000471	0.0009	CcSEcCtD
Cabergoline—Vomiting—Gemcitabine—pancreatic cancer	0.00047	0.000898	CcSEcCtD
Cabergoline—Dyspnoea—Docetaxel—pancreatic cancer	0.000468	0.000893	CcSEcCtD
Cabergoline—Somnolence—Docetaxel—pancreatic cancer	0.000467	0.000891	CcSEcCtD
Cabergoline—Rash—Gemcitabine—pancreatic cancer	0.000466	0.00089	CcSEcCtD
Cabergoline—Dermatitis—Gemcitabine—pancreatic cancer	0.000466	0.00089	CcSEcCtD
Cabergoline—Headache—Gemcitabine—pancreatic cancer	0.000463	0.000885	CcSEcCtD
Cabergoline—Cardiac disorder—Epirubicin—pancreatic cancer	0.000462	0.000883	CcSEcCtD
Cabergoline—Vomiting—Fluorouracil—pancreatic cancer	0.000462	0.000883	CcSEcCtD
Cabergoline—Rhinitis—Doxorubicin—pancreatic cancer	0.000462	0.000883	CcSEcCtD
Cabergoline—Dyspepsia—Docetaxel—pancreatic cancer	0.000462	0.000882	CcSEcCtD
Cabergoline—Rash—Fluorouracil—pancreatic cancer	0.000459	0.000875	CcSEcCtD
Cabergoline—Dermatitis—Fluorouracil—pancreatic cancer	0.000458	0.000875	CcSEcCtD
Cabergoline—Decreased appetite—Docetaxel—pancreatic cancer	0.000456	0.000871	CcSEcCtD
Cabergoline—Headache—Fluorouracil—pancreatic cancer	0.000456	0.00087	CcSEcCtD
Cabergoline—Oedema peripheral—Doxorubicin—pancreatic cancer	0.000454	0.000867	CcSEcCtD
Cabergoline—Fatigue—Docetaxel—pancreatic cancer	0.000453	0.000864	CcSEcCtD
Cabergoline—Nausea—Irinotecan—pancreatic cancer	0.000451	0.000861	CcSEcCtD
Cabergoline—Pain—Docetaxel—pancreatic cancer	0.000449	0.000857	CcSEcCtD
Cabergoline—Constipation—Docetaxel—pancreatic cancer	0.000449	0.000857	CcSEcCtD
Cabergoline—Arrhythmia—Epirubicin—pancreatic cancer	0.000445	0.00085	CcSEcCtD
Cabergoline—Visual impairment—Doxorubicin—pancreatic cancer	0.000444	0.000848	CcSEcCtD
Cabergoline—Alopecia—Epirubicin—pancreatic cancer	0.00044	0.000841	CcSEcCtD
Cabergoline—Nausea—Gemcitabine—pancreatic cancer	0.000439	0.000839	CcSEcCtD
Cabergoline—Feeling abnormal—Docetaxel—pancreatic cancer	0.000433	0.000826	CcSEcCtD
Cabergoline—Nausea—Fluorouracil—pancreatic cancer	0.000432	0.000825	CcSEcCtD
Cabergoline—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.000429	0.000819	CcSEcCtD
Cabergoline—Cardiac disorder—Doxorubicin—pancreatic cancer	0.000428	0.000817	CcSEcCtD
Cabergoline—Flatulence—Epirubicin—pancreatic cancer	0.000427	0.000816	CcSEcCtD
Cabergoline—Tension—Epirubicin—pancreatic cancer	0.000426	0.000813	CcSEcCtD
Cabergoline—Nervousness—Epirubicin—pancreatic cancer	0.000421	0.000804	CcSEcCtD
Cabergoline—Back pain—Epirubicin—pancreatic cancer	0.00042	0.000801	CcSEcCtD
Cabergoline—Muscle spasms—Epirubicin—pancreatic cancer	0.000417	0.000796	CcSEcCtD
Cabergoline—Abdominal pain—Docetaxel—pancreatic cancer	0.000415	0.000792	CcSEcCtD
Cabergoline—Arrhythmia—Doxorubicin—pancreatic cancer	0.000412	0.000786	CcSEcCtD
Cabergoline—Alopecia—Doxorubicin—pancreatic cancer	0.000407	0.000778	CcSEcCtD
Cabergoline—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000403	0.000768	CcSEcCtD
Cabergoline—Flatulence—Doxorubicin—pancreatic cancer	0.000396	0.000755	CcSEcCtD
Cabergoline—Tension—Doxorubicin—pancreatic cancer	0.000394	0.000752	CcSEcCtD
Cabergoline—Malaise—Epirubicin—pancreatic cancer	0.000391	0.000747	CcSEcCtD
Cabergoline—Nervousness—Doxorubicin—pancreatic cancer	0.00039	0.000744	CcSEcCtD
Cabergoline—Vertigo—Epirubicin—pancreatic cancer	0.00039	0.000744	CcSEcCtD
Cabergoline—Syncope—Epirubicin—pancreatic cancer	0.000389	0.000743	CcSEcCtD
Cabergoline—Back pain—Doxorubicin—pancreatic cancer	0.000388	0.000741	CcSEcCtD
Cabergoline—Hypersensitivity—Docetaxel—pancreatic cancer	0.000387	0.000738	CcSEcCtD
Cabergoline—Muscle spasms—Doxorubicin—pancreatic cancer	0.000386	0.000737	CcSEcCtD
Cabergoline—Palpitations—Epirubicin—pancreatic cancer	0.000383	0.000732	CcSEcCtD
Cabergoline—Loss of consciousness—Epirubicin—pancreatic cancer	0.000381	0.000728	CcSEcCtD
Cabergoline—Asthenia—Docetaxel—pancreatic cancer	0.000377	0.000719	CcSEcCtD
Cabergoline—HTR7—enteric nervous system—pancreatic cancer	0.000377	0.5	CbGeAlD
Cabergoline—Hypertension—Epirubicin—pancreatic cancer	0.000375	0.000715	CcSEcCtD
Cabergoline—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000372	0.000711	CcSEcCtD
Cabergoline—Pruritus—Docetaxel—pancreatic cancer	0.000371	0.000709	CcSEcCtD
Cabergoline—Arthralgia—Epirubicin—pancreatic cancer	0.000369	0.000705	CcSEcCtD
Cabergoline—Anxiety—Epirubicin—pancreatic cancer	0.000368	0.000703	CcSEcCtD
Cabergoline—Discomfort—Epirubicin—pancreatic cancer	0.000365	0.000697	CcSEcCtD
Cabergoline—Malaise—Doxorubicin—pancreatic cancer	0.000362	0.000691	CcSEcCtD
Cabergoline—Dry mouth—Epirubicin—pancreatic cancer	0.000361	0.00069	CcSEcCtD
Cabergoline—Vertigo—Doxorubicin—pancreatic cancer	0.000361	0.000688	CcSEcCtD
Cabergoline—Syncope—Doxorubicin—pancreatic cancer	0.00036	0.000687	CcSEcCtD
Cabergoline—Diarrhoea—Docetaxel—pancreatic cancer	0.000359	0.000686	CcSEcCtD
Cabergoline—Confusional state—Epirubicin—pancreatic cancer	0.000357	0.000682	CcSEcCtD
Cabergoline—Palpitations—Doxorubicin—pancreatic cancer	0.000355	0.000677	CcSEcCtD
Cabergoline—Oedema—Epirubicin—pancreatic cancer	0.000354	0.000676	CcSEcCtD
Cabergoline—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000353	0.000674	CcSEcCtD
Cabergoline—Shock—Epirubicin—pancreatic cancer	0.000348	0.000665	CcSEcCtD
Cabergoline—Dizziness—Docetaxel—pancreatic cancer	0.000347	0.000663	CcSEcCtD
Cabergoline—Hypertension—Doxorubicin—pancreatic cancer	0.000347	0.000662	CcSEcCtD
Cabergoline—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000342	0.000653	CcSEcCtD
Cabergoline—Arthralgia—Doxorubicin—pancreatic cancer	0.000342	0.000652	CcSEcCtD
Cabergoline—Anxiety—Doxorubicin—pancreatic cancer	0.000341	0.00065	CcSEcCtD
Cabergoline—Discomfort—Doxorubicin—pancreatic cancer	0.000338	0.000645	CcSEcCtD
Cabergoline—Anorexia—Epirubicin—pancreatic cancer	0.000337	0.000644	CcSEcCtD
Cabergoline—Dry mouth—Doxorubicin—pancreatic cancer	0.000334	0.000638	CcSEcCtD
Cabergoline—Vomiting—Docetaxel—pancreatic cancer	0.000334	0.000637	CcSEcCtD
Cabergoline—Rash—Docetaxel—pancreatic cancer	0.000331	0.000632	CcSEcCtD
Cabergoline—Hypotension—Epirubicin—pancreatic cancer	0.000331	0.000632	CcSEcCtD
Cabergoline—Dermatitis—Docetaxel—pancreatic cancer	0.000331	0.000631	CcSEcCtD
Cabergoline—Confusional state—Doxorubicin—pancreatic cancer	0.00033	0.000631	CcSEcCtD
Cabergoline—Headache—Docetaxel—pancreatic cancer	0.000329	0.000628	CcSEcCtD
Cabergoline—Oedema—Doxorubicin—pancreatic cancer	0.000328	0.000625	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000323	0.000616	CcSEcCtD
Cabergoline—Shock—Doxorubicin—pancreatic cancer	0.000322	0.000615	CcSEcCtD
Cabergoline—Insomnia—Epirubicin—pancreatic cancer	0.00032	0.000611	CcSEcCtD
Cabergoline—Paraesthesia—Epirubicin—pancreatic cancer	0.000318	0.000607	CcSEcCtD
Cabergoline—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000317	0.000605	CcSEcCtD
Cabergoline—Dyspnoea—Epirubicin—pancreatic cancer	0.000316	0.000603	CcSEcCtD
Cabergoline—Somnolence—Epirubicin—pancreatic cancer	0.000315	0.000601	CcSEcCtD
Cabergoline—Anorexia—Doxorubicin—pancreatic cancer	0.000312	0.000596	CcSEcCtD
Cabergoline—Nausea—Docetaxel—pancreatic cancer	0.000312	0.000595	CcSEcCtD
Cabergoline—Dyspepsia—Epirubicin—pancreatic cancer	0.000312	0.000595	CcSEcCtD
Cabergoline—Decreased appetite—Epirubicin—pancreatic cancer	0.000308	0.000588	CcSEcCtD
Cabergoline—Hypotension—Doxorubicin—pancreatic cancer	0.000306	0.000584	CcSEcCtD
Cabergoline—Fatigue—Epirubicin—pancreatic cancer	0.000305	0.000583	CcSEcCtD
Cabergoline—Pain—Epirubicin—pancreatic cancer	0.000303	0.000578	CcSEcCtD
Cabergoline—Constipation—Epirubicin—pancreatic cancer	0.000303	0.000578	CcSEcCtD
Cabergoline—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000298	0.00057	CcSEcCtD
Cabergoline—Insomnia—Doxorubicin—pancreatic cancer	0.000296	0.000566	CcSEcCtD
Cabergoline—Paraesthesia—Doxorubicin—pancreatic cancer	0.000294	0.000562	CcSEcCtD
Cabergoline—Dyspnoea—Doxorubicin—pancreatic cancer	0.000292	0.000558	CcSEcCtD
Cabergoline—Feeling abnormal—Epirubicin—pancreatic cancer	0.000292	0.000557	CcSEcCtD
Cabergoline—Somnolence—Doxorubicin—pancreatic cancer	0.000291	0.000556	CcSEcCtD
Cabergoline—Gastrointestinal pain—Epirubicin—pancreatic cancer	0.00029	0.000553	CcSEcCtD
Cabergoline—Dyspepsia—Doxorubicin—pancreatic cancer	0.000288	0.000551	CcSEcCtD
Cabergoline—Decreased appetite—Doxorubicin—pancreatic cancer	0.000285	0.000544	CcSEcCtD
Cabergoline—Fatigue—Doxorubicin—pancreatic cancer	0.000282	0.000539	CcSEcCtD
Cabergoline—Pain—Doxorubicin—pancreatic cancer	0.00028	0.000535	CcSEcCtD
Cabergoline—Constipation—Doxorubicin—pancreatic cancer	0.00028	0.000535	CcSEcCtD
Cabergoline—Abdominal pain—Epirubicin—pancreatic cancer	0.00028	0.000534	CcSEcCtD
Cabergoline—Feeling abnormal—Doxorubicin—pancreatic cancer	0.00027	0.000515	CcSEcCtD
Cabergoline—Gastrointestinal pain—Doxorubicin—pancreatic cancer	0.000268	0.000511	CcSEcCtD
Cabergoline—Hypersensitivity—Epirubicin—pancreatic cancer	0.000261	0.000498	CcSEcCtD
Cabergoline—Abdominal pain—Doxorubicin—pancreatic cancer	0.000259	0.000494	CcSEcCtD
Cabergoline—Asthenia—Epirubicin—pancreatic cancer	0.000254	0.000485	CcSEcCtD
Cabergoline—Pruritus—Epirubicin—pancreatic cancer	0.00025	0.000478	CcSEcCtD
Cabergoline—Diarrhoea—Epirubicin—pancreatic cancer	0.000242	0.000462	CcSEcCtD
Cabergoline—Hypersensitivity—Doxorubicin—pancreatic cancer	0.000241	0.000461	CcSEcCtD
Cabergoline—Asthenia—Doxorubicin—pancreatic cancer	0.000235	0.000449	CcSEcCtD
Cabergoline—HTR2A—enteric nervous system—pancreatic cancer	0.000235	0.312	CbGeAlD
Cabergoline—Dizziness—Epirubicin—pancreatic cancer	0.000234	0.000447	CcSEcCtD
Cabergoline—Pruritus—Doxorubicin—pancreatic cancer	0.000232	0.000442	CcSEcCtD
Cabergoline—Vomiting—Epirubicin—pancreatic cancer	0.000225	0.00043	CcSEcCtD
Cabergoline—Diarrhoea—Doxorubicin—pancreatic cancer	0.000224	0.000428	CcSEcCtD
Cabergoline—Rash—Epirubicin—pancreatic cancer	0.000223	0.000426	CcSEcCtD
Cabergoline—Dermatitis—Epirubicin—pancreatic cancer	0.000223	0.000426	CcSEcCtD
Cabergoline—Headache—Epirubicin—pancreatic cancer	0.000222	0.000423	CcSEcCtD
Cabergoline—Dizziness—Doxorubicin—pancreatic cancer	0.000217	0.000414	CcSEcCtD
Cabergoline—Nausea—Epirubicin—pancreatic cancer	0.00021	0.000401	CcSEcCtD
Cabergoline—Vomiting—Doxorubicin—pancreatic cancer	0.000208	0.000398	CcSEcCtD
Cabergoline—Rash—Doxorubicin—pancreatic cancer	0.000207	0.000394	CcSEcCtD
Cabergoline—Dermatitis—Doxorubicin—pancreatic cancer	0.000206	0.000394	CcSEcCtD
Cabergoline—Headache—Doxorubicin—pancreatic cancer	0.000205	0.000392	CcSEcCtD
Cabergoline—Nausea—Doxorubicin—pancreatic cancer	0.000195	0.000371	CcSEcCtD
Cabergoline—ADRA2A—islet of Langerhans—pancreatic cancer	2.64e-05	0.0351	CbGeAlD
Cabergoline—HTR2B—digestive system—pancreatic cancer	2.52e-05	0.0335	CbGeAlD
Cabergoline—ADRA2C—pancreas—pancreatic cancer	2.33e-05	0.0309	CbGeAlD
Cabergoline—HTR7—digestive system—pancreatic cancer	2.16e-05	0.0287	CbGeAlD
Cabergoline—ADRA2A—pancreas—pancreatic cancer	1.86e-05	0.0247	CbGeAlD
Cabergoline—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	1.41e-05	2.96e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	1.41e-05	2.96e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	1.41e-05	2.96e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.4e-05	2.96e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling by GPCR—AKT1—pancreatic cancer	1.4e-05	2.95e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	1.4e-05	2.94e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—CTNNB1—pancreatic cancer	1.4e-05	2.93e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—KRAS—pancreatic cancer	1.39e-05	2.93e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CCND1—pancreatic cancer	1.39e-05	2.92e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.38e-05	2.89e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—CTNNB1—pancreatic cancer	1.37e-05	2.89e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CXCL8—pancreatic cancer	1.37e-05	2.89e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	1.37e-05	2.88e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MMP9—pancreatic cancer	1.37e-05	2.88e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	1.36e-05	2.87e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—HRAS—pancreatic cancer	1.36e-05	2.87e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—SRC—pancreatic cancer	1.36e-05	2.87e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—PTEN—pancreatic cancer	1.36e-05	2.86e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—MYC—pancreatic cancer	1.36e-05	2.86e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TGFB1—pancreatic cancer	1.35e-05	2.85e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	1.35e-05	2.84e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—SRC—pancreatic cancer	1.35e-05	2.84e-05	CbGpPWpGaD
Cabergoline—HTR2A—digestive system—pancreatic cancer	1.35e-05	0.0179	CbGeAlD
Cabergoline—ADRA1B—Signaling Pathways—MMP9—pancreatic cancer	1.35e-05	2.83e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—STK11—pancreatic cancer	1.35e-05	2.83e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	1.34e-05	2.82e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—MYC—pancreatic cancer	1.34e-05	2.82e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—MYC—pancreatic cancer	1.34e-05	2.82e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PTEN—pancreatic cancer	1.34e-05	2.81e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—PIK3CA—pancreatic cancer	1.34e-05	2.81e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TGFB1—pancreatic cancer	1.34e-05	2.81e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TGFB1—pancreatic cancer	1.34e-05	2.81e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—SRC—pancreatic cancer	1.33e-05	2.8e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	1.33e-05	2.8e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.33e-05	2.8e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—EGFR—pancreatic cancer	1.33e-05	2.79e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—VEGFA—pancreatic cancer	1.33e-05	2.79e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling by GPCR—AKT1—pancreatic cancer	1.33e-05	2.79e-05	CbGpPWpGaD
Cabergoline—DRD2—GPCR downstream signaling—AKT1—pancreatic cancer	1.33e-05	2.79e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	1.32e-05	2.78e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PTEN—pancreatic cancer	1.32e-05	2.78e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	1.32e-05	2.77e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—VEGFA—pancreatic cancer	1.31e-05	2.77e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—STAT3—pancreatic cancer	1.31e-05	2.76e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	1.31e-05	2.76e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CASP3—pancreatic cancer	1.31e-05	2.76e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—NRAS—pancreatic cancer	1.31e-05	2.76e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—EGFR—pancreatic cancer	1.31e-05	2.76e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—EGFR—pancreatic cancer	1.31e-05	2.76e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling by GPCR—AKT1—pancreatic cancer	1.31e-05	2.75e-05	CbGpPWpGaD
Cabergoline—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.3e-05	2.74e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—SRC—pancreatic cancer	1.3e-05	2.74e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—STAT3—pancreatic cancer	1.3e-05	2.74e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—PIK3CA—pancreatic cancer	1.3e-05	2.74e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—NRAS—pancreatic cancer	1.3e-05	2.73e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—VEGFA—pancreatic cancer	1.3e-05	2.73e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—SRC—pancreatic cancer	1.3e-05	2.73e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—TP53—pancreatic cancer	1.29e-05	2.72e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	1.29e-05	2.72e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—TP53—pancreatic cancer	1.29e-05	2.7e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—STAT3—pancreatic cancer	1.29e-05	2.7e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—NRAS—pancreatic cancer	1.28e-05	2.7e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—PIK3CA—pancreatic cancer	1.28e-05	2.69e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CCND1—pancreatic cancer	1.28e-05	2.69e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	1.28e-05	2.69e-05	CbGpPWpGaD
Cabergoline—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	1.28e-05	2.69e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	1.27e-05	2.67e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—CTNNB1—pancreatic cancer	1.27e-05	2.66e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	1.27e-05	2.66e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	1.26e-05	2.66e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—SRC—pancreatic cancer	1.26e-05	2.65e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—TP53—pancreatic cancer	1.26e-05	2.65e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	1.26e-05	2.65e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	1.26e-05	2.64e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—KRAS—pancreatic cancer	1.25e-05	2.64e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	1.25e-05	2.64e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	1.25e-05	2.63e-05	CbGpPWpGaD
Cabergoline—CYP3A4—digestive system—pancreatic cancer	1.25e-05	0.0166	CbGeAlD
Cabergoline—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	1.25e-05	2.62e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.25e-05	2.62e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—SRC—pancreatic cancer	1.24e-05	2.61e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MMP9—pancreatic cancer	1.24e-05	2.61e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—TP53—pancreatic cancer	1.24e-05	2.61e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—KRAS—pancreatic cancer	1.24e-05	2.6e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—KRAS—pancreatic cancer	1.24e-05	2.6e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—HRAS—pancreatic cancer	1.24e-05	2.6e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PTEN—pancreatic cancer	1.23e-05	2.6e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	1.23e-05	2.59e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—HRAS—pancreatic cancer	1.23e-05	2.59e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	1.23e-05	2.58e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—VEGFA—pancreatic cancer	1.23e-05	2.58e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.22e-05	2.57e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	1.22e-05	2.57e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—MYC—pancreatic cancer	1.22e-05	2.57e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	1.22e-05	2.57e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.22e-05	2.57e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TGFB1—pancreatic cancer	1.22e-05	2.56e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—STAT3—pancreatic cancer	1.22e-05	2.56e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	1.21e-05	2.55e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—NRAS—pancreatic cancer	1.21e-05	2.55e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—MYC—pancreatic cancer	1.21e-05	2.54e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—VEGFA—pancreatic cancer	1.21e-05	2.54e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TGFB1—pancreatic cancer	1.21e-05	2.54e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—HRAS—pancreatic cancer	1.2e-05	2.53e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling by GPCR—AKT1—pancreatic cancer	1.2e-05	2.53e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—STAT3—pancreatic cancer	1.2e-05	2.52e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	1.2e-05	2.51e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—MYC—pancreatic cancer	1.19e-05	2.51e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—EGFR—pancreatic cancer	1.19e-05	2.51e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—NRAS—pancreatic cancer	1.19e-05	2.51e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TGFB1—pancreatic cancer	1.19e-05	2.51e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	1.19e-05	2.5e-05	CbGpPWpGaD
Cabergoline—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	1.19e-05	2.5e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—HRAS—pancreatic cancer	1.18e-05	2.49e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	1.18e-05	2.49e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—EGFR—pancreatic cancer	1.18e-05	2.49e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—TP53—pancreatic cancer	1.18e-05	2.49e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	1.18e-05	2.47e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—EGFR—pancreatic cancer	1.17e-05	2.46e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—MYC—pancreatic cancer	1.17e-05	2.46e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	1.17e-05	2.45e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—MYC—pancreatic cancer	1.16e-05	2.44e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	1.16e-05	2.44e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	1.16e-05	2.44e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—TYMS—pancreatic cancer	1.16e-05	2.44e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—PIK3CA—pancreatic cancer	1.15e-05	2.42e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—PIK3CA—pancreatic cancer	1.15e-05	2.41e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	1.14e-05	2.41e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—SRC—pancreatic cancer	1.14e-05	2.41e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	1.14e-05	2.4e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—PIK3CA—pancreatic cancer	1.14e-05	2.39e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—PIK3CA—pancreatic cancer	1.14e-05	2.39e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	1.14e-05	2.39e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	1.13e-05	2.38e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	1.13e-05	2.38e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—MYC—pancreatic cancer	1.13e-05	2.38e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—KRAS—pancreatic cancer	1.13e-05	2.37e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TGFB1—pancreatic cancer	1.13e-05	2.37e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—SRC—pancreatic cancer	1.13e-05	2.37e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—KRAS—pancreatic cancer	1.12e-05	2.35e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—TP53—pancreatic cancer	1.12e-05	2.35e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—VEGFA—pancreatic cancer	1.11e-05	2.34e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—MYC—pancreatic cancer	1.11e-05	2.34e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	1.11e-05	2.34e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TGFB1—pancreatic cancer	1.11e-05	2.33e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—EGFR—pancreatic cancer	1.11e-05	2.32e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	1.1e-05	2.32e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—KRAS—pancreatic cancer	1.1e-05	2.32e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—STAT3—pancreatic cancer	1.1e-05	2.32e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	1.1e-05	2.32e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—NRAS—pancreatic cancer	1.1e-05	2.32e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—TP53—pancreatic cancer	1.1e-05	2.31e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—TP53—pancreatic cancer	1.1e-05	2.31e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	1.1e-05	2.31e-05	CbGpPWpGaD
Cabergoline—HTR7—Signaling Pathways—AKT1—pancreatic cancer	1.09e-05	2.3e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—EGFR—pancreatic cancer	1.09e-05	2.29e-05	CbGpPWpGaD
Cabergoline—HTR1D—Signaling Pathways—AKT1—pancreatic cancer	1.09e-05	2.28e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	1.09e-05	2.28e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	1.08e-05	2.28e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	1.08e-05	2.27e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	1.08e-05	2.27e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	1.07e-05	2.26e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	1.07e-05	2.26e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—HRAS—pancreatic cancer	1.07e-05	2.24e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	1.06e-05	2.24e-05	CbGpPWpGaD
Cabergoline—HTR1B—Signaling Pathways—AKT1—pancreatic cancer	1.06e-05	2.24e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	1.06e-05	2.23e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—HRAS—pancreatic cancer	1.05e-05	2.21e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—HRAS—pancreatic cancer	1.05e-05	2.21e-05	CbGpPWpGaD
Cabergoline—DRD4—Signaling Pathways—AKT1—pancreatic cancer	1.05e-05	2.2e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—KRAS—pancreatic cancer	1.04e-05	2.2e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—PIK3CA—pancreatic cancer	1.04e-05	2.18e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—KRAS—pancreatic cancer	1.03e-05	2.16e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—PIK3CA—pancreatic cancer	1.03e-05	2.16e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—MYC—pancreatic cancer	1.03e-05	2.16e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	1.02e-05	2.15e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TGFB1—pancreatic cancer	1.02e-05	2.15e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—PIK3CA—pancreatic cancer	1.01e-05	2.13e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—MYC—pancreatic cancer	1.01e-05	2.12e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	1.01e-05	2.12e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—EGFR—pancreatic cancer	1e-05	2.11e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—TP53—pancreatic cancer	1e-05	2.11e-05	CbGpPWpGaD
Cabergoline—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	9.99e-06	2.1e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	9.98e-06	2.1e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—TP53—pancreatic cancer	9.94e-06	2.09e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	9.91e-06	2.09e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	9.88e-06	2.08e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	9.88e-06	2.08e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	9.87e-06	2.08e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	9.86e-06	2.07e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	9.86e-06	2.07e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	9.85e-06	2.07e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—TP53—pancreatic cancer	9.81e-06	2.06e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	9.66e-06	2.03e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—PIK3CA—pancreatic cancer	9.59e-06	2.02e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—TP53—pancreatic cancer	9.59e-06	2.02e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—HRAS—pancreatic cancer	9.59e-06	2.02e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—TP53—pancreatic cancer	9.54e-06	2.01e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—HRAS—pancreatic cancer	9.5e-06	2e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—KRAS—pancreatic cancer	9.47e-06	1.99e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—PIK3CA—pancreatic cancer	9.44e-06	1.99e-05	CbGpPWpGaD
Cabergoline—DRD1—Signaling Pathways—AKT1—pancreatic cancer	9.42e-06	1.98e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—APOE—pancreatic cancer	9.42e-06	1.98e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—HRAS—pancreatic cancer	9.38e-06	1.97e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Metabolism—AKT1—pancreatic cancer	9.37e-06	1.97e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	9.32e-06	1.96e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	9.32e-06	1.96e-05	CbGpPWpGaD
Cabergoline—DRD3—Signaling Pathways—AKT1—pancreatic cancer	9.29e-06	1.95e-05	CbGpPWpGaD
Cabergoline—ADRA1D—Signaling Pathways—AKT1—pancreatic cancer	9.29e-06	1.95e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—TP53—pancreatic cancer	9.28e-06	1.95e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	9.18e-06	1.93e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	9.17e-06	1.93e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	9.16e-06	1.93e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—TP53—pancreatic cancer	9.13e-06	1.92e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	9.13e-06	1.92e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	9.13e-06	1.92e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	8.98e-06	1.89e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—HRAS—pancreatic cancer	8.88e-06	1.87e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—HRAS—pancreatic cancer	8.74e-06	1.84e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—PIK3CA—pancreatic cancer	8.7e-06	1.83e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	8.56e-06	1.8e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	8.5e-06	1.79e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	8.48e-06	1.78e-05	CbGpPWpGaD
Cabergoline—ADRB1—Signaling Pathways—AKT1—pancreatic cancer	8.47e-06	1.78e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—TP53—pancreatic cancer	8.42e-06	1.77e-05	CbGpPWpGaD
Cabergoline—ADRA2B—Signaling Pathways—AKT1—pancreatic cancer	8.39e-06	1.76e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	8.39e-06	1.76e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—TP53—pancreatic cancer	8.29e-06	1.74e-05	CbGpPWpGaD
Cabergoline—ADRB2—Signaling Pathways—AKT1—pancreatic cancer	8.28e-06	1.74e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PPARG—pancreatic cancer	8.2e-06	1.73e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	8.11e-06	1.71e-05	CbGpPWpGaD
Cabergoline—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	8.1e-06	1.7e-05	CbGpPWpGaD
Cabergoline—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	8.06e-06	1.69e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—HRAS—pancreatic cancer	8.05e-06	1.69e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	7.92e-06	1.67e-05	CbGpPWpGaD
Cabergoline—ADRA2C—Signaling Pathways—AKT1—pancreatic cancer	7.84e-06	1.65e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	7.79e-06	1.64e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	7.76e-06	1.63e-05	CbGpPWpGaD
Cabergoline—ADRA1B—Signaling Pathways—AKT1—pancreatic cancer	7.71e-06	1.62e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Metabolism—AKT1—pancreatic cancer	7.61e-06	1.6e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	7.54e-06	1.59e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	7.47e-06	1.57e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	7.21e-06	1.52e-05	CbGpPWpGaD
Cabergoline—DRD2—Signaling Pathways—AKT1—pancreatic cancer	7.11e-06	1.5e-05	CbGpPWpGaD
Cabergoline—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	7e-06	1.47e-05	CbGpPWpGaD
Cabergoline—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	6.85e-06	1.44e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	6.51e-06	1.37e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTGS2—pancreatic cancer	6.45e-06	1.36e-05	CbGpPWpGaD
Cabergoline—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	6.37e-06	1.34e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PTEN—pancreatic cancer	5.63e-06	1.18e-05	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	3.97e-06	8.35e-06	CbGpPWpGaD
Cabergoline—CYP3A4—Metabolism—AKT1—pancreatic cancer	3.24e-06	6.82e-06	CbGpPWpGaD
